{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:30:23Z","timestamp":1759815023888},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.canlet.2013.01.004","type":"journal-article","created":{"date-parts":[[2013,1,20]],"date-time":"2013-01-20T13:01:15Z","timestamp":1358686875000},"page":"220-229","source":"Crossref","is-referenced-by-count":17,"title":["Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells"],"prefix":"10.1016","volume":"331","author":[{"given":"Tetsuo","family":"Nishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michitaka","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Kodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2010","key":"10.1016\/j.canlet.2013.01.004_b0005","first-page":"2893","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN","volume":"127","author":"Ferlay","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.canlet.2013.01.004_b0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1634\/theoncologist.10-90003-49","article-title":"Evolving chemotherapy for advanced gastric cancer","volume":"10","author":"Ajani","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2013.01.004_b0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00432-008-0425-z","article-title":"Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction","volume":"135","author":"Menges","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.01.004_b0020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0959-8049(97)86090-X","article-title":"Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer","volume":"15","author":"Webb","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.01.004_b0025","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2002.08.105","article-title":"Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer","volume":"20","author":"Ross","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.01.004_b0030","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","article-title":"Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial","volume":"20","author":"Kang","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2013.01.004_b0035","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.01.004_b0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"U.G.C.S.G.o.t.N.C.R.I.o.t.U. Kingdom, Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2013.01.004_b0045","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.01.004_b0050","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1091\/mbc.01-12-0584","article-title":"Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake","volume":"13","author":"Edinger","year":"2002","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.canlet.2013.01.004_b0055","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/MCB.24.1.200-216.2004","article-title":"MTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1\/eukaryotic translation initiation factor 4E","volume":"24","author":"Fingar","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2013.01.004_b0060","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1158\/1078-0432.CCR-06-2254","article-title":"Targeting von Hippel-Lindau pathway in renal cell carcinoma","volume":"12","author":"Patel","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.01.004_b0065","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2013.01.004_b0070","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S1471-4914(01)02161-X","article-title":"PI 3-kinase, mTOR, protein synthesis and cancer","volume":"7","author":"Vogt","year":"2001","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.canlet.2013.01.004_b0075","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1101\/gad.887201","article-title":"Regulation of translation initiation by FRAP\/mTOR","volume":"15","author":"Gingras","year":"2001","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2013.01.004_b0080","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1101\/gad.995802","article-title":"Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1\/eIF4E","volume":"16","author":"Fingar","year":"2002","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2013.01.004_b0085","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1038\/sj.onc.1207549","article-title":"EIF4E-from translation to transformation","volume":"23","author":"Mamane","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2013.01.004_b0090","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/ijc.22442","article-title":"Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model","volume":"120","author":"Lang","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2013.01.004_b0095","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2559.2008.03021.x","article-title":"EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number","volume":"52","author":"Kim","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.canlet.2013.01.004_b0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1245\/s10434-007-9596-0","article-title":"Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients","volume":"15","author":"Lieto","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.canlet.2013.01.004_b0105","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/1078-0432.CCR-07-1898","article-title":"Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer","volume":"14","author":"Matsubara","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.01.004_b0110","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2013.01.004_b0115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2013.01.004_b0120","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1357-2725(00)00007-8","article-title":"4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers","volume":"32","author":"Mart\u00edn","year":"2000","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.canlet.2013.01.004_b0125","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4161\/cbt.7.9.6416","article-title":"Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo","volume":"7","author":"Cejka","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2013.01.004_b0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jjco\/hyp120","article-title":"Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors","volume":"40","author":"Okamoto","year":"2010","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.01.004_b0135","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2009.26.2923","article-title":"Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer","volume":"28","author":"Doi","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.01.004_b0140","doi-asserted-by":"crossref","unstructured":"Eric Van Cutsem, K.-H. Yeh, Y.-J. Bang, L. Shen, J.A. Ajani, Y.-X. Bai, H.C. Chung, H.-M. Pan, K. Chin, K. Muro, Y.H. Kim, H. Smith, C. Costantini, S. Musalli, S. Rizvi, T. Sahmoud, A. Ohtsu, Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1, J. Clin. Oncol. (suppl. 4) (2012) (abstr LBA3).","DOI":"10.1200\/jco.2012.30.4_suppl.lba3"},{"key":"10.1016\/j.canlet.2013.01.004_b0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.canlet.2010.07.020","article-title":"RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase","volume":"299","author":"Lee","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2013.01.004_b0150","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/1078-0432.CCR-03-0043","article-title":"Determinants of rapamycin sensitivity in breast cancer cells","volume":"10","author":"Noh","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.01.004_b0155","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.4161\/cbt.8.24.9987","article-title":"Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer","volume":"8","author":"Mansure","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2013.01.004_b0160","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.4161\/cbt.7.12.6944","article-title":"Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors\u2019 anticancer efficacy","volume":"7","author":"Wang","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2013.01.004_b0165","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1126\/science.1187532","article-title":"MTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs","volume":"328","author":"Dowling","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.canlet.2013.01.004_b0170","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1101\/gad.13.11.1422","article-title":"Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism","volume":"13","author":"Gingras","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2013.01.004_b0175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/BJ20090489","article-title":"Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin","volume":"421","author":"Garc\u00eda-Mart\u00ednez","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.canlet.2013.01.004_b0180","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1128\/MCB.00980-08","article-title":"The TSC-mTOR pathway mediates translational activation of TOP mRNAs by insulin largely in a raptor- or rictor-independent manner","volume":"29","author":"Patursky-Polischuk","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.canlet.2013.01.004_b0185","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Choo","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2013.01.004_b0190","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.01.004_b0195","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2013.01.004_b0200","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Ohtsu","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2013.01.004_b0205","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/bjc.2012.47","article-title":"Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum","volume":"106","author":"Yoon","year":"2012","journal-title":"Br. J. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T14:27:29Z","timestamp":1562596049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383513000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0304383513000244"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2013.01.004","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}